ArticleKidney international reports2022

Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.

Stanley C Jordan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.